Phase 1 Eczema Trial, Recruiting (NCT07411755)

Phase 1 Eczema Trial, Recruiting NCT07411755 Sponsor: Jiangsu Genscend Biopharmaceutical Co., Ltd Condition: Eczema

Printed from Voxsanity (voxsanity.com.au) — NCT07411755 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Eczema

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have no significant health problems found during a physical check-up, heart tracing (ECG), chest X-ray, or blood/urine tests before the study begins.
Your body mass index (BMI) is between 19 and 26, and you weigh between 55 and 85 kilograms (roughly 121 to 187 pounds).
You and your partner agree to use reliable contraception from the time you sign the consent form until three months after receiving the study treatment, and neither you nor your partner has plans for pregnancy or sperm donation during this time.

Who may not be able to join:

You have a history of, or currently have, a significant disease affecting the brain, nerves, lungs, heart, stomach, blood, hormones, muscles, joints, or any other condition that the study doctor thinks could affect the results.
You have a history of allergies to two or more drugs or foods, certain allergic conditions such as asthma, hives, or eczema, or a known allergy to medicines similar to the one being studied (confirm with trial site).
Your screening blood tests come back positive for HIV, hepatitis B, hepatitis C, or syphilis.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +086-15800767550

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07411755

Sponsor: Jiangsu Genscend Biopharmaceutical Co., Ltd

Phase: Phase 1

Status: Recruiting

Condition: Eczema

Trial contact: +086-15800767550

More information: https://clinicaltrials.gov/study/NCT07411755

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have no significant health problems found during a physical check-up, heart tracing (ECG), chest X-ray, or blood/urine tests before the study begins.
Your body mass index (BMI) is between 19 and 26, and you weigh between 55 and 85 kilograms (roughly 121 to 187 pounds).
You and your partner agree to use reliable contraception from the time you sign the consent form until three months after receiving the study treatment, and neither you nor your partner has plans for pregnancy or sperm donation during this time.

Who may not be able to join:

You have a history of, or currently have, a significant disease affecting the brain, nerves, lungs, heart, stomach, blood, hormones, muscles, joints, or any other condition that the study doctor thinks could affect the results.
You have a history of allergies to two or more drugs or foods, certain allergic conditions such as asthma, hives, or eczema, or a known allergy to medicines similar to the one being studied (confirm with trial site).
Your screening blood tests come back positive for HIV, hepatitis B, hepatitis C, or syphilis.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Jiangsu Genscend Biopharmaceutical Co., Ltd

Registry

ClinicalTrials.gov

Start date

5 March 2026

Est. completion

1 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Pharmacokinetics Endpoint; Pharmacokinetics Endpoint; Pharmacokinetics Endpoint

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov